Selected articles
Articles for label Hakl Marek are displayed.. Show all articles
IR oxycodone in the treatment of breakthrough pain
02/2019 MUDr. Marek Hakl, Ph.D.
Breakthrough pain affects 60-85% of patients and is characterized by onset within seconds to minutes and short duration. We consider breakthrough pain as a sudden, transient, and short-lasting pain that occurs in opioid-treated patients. Breakthrough pain is a temporary worsening of pain in patients with well-controlled underlying pain. Poorly controlled breakthrough pain has a very negative impact on the quality of life of patients. The current treatment options for breakthrough pain include the use of transmucosal fentanyl and, in addition, IR oxycodone. Oxycodone has a relatively rapid onset of action, is well tolerated and easily titrated. It is a welcome enrichment of therapeutic options for treatment of oncological and non-oncological breakthrough pain.
ENTIRE ARTICLE
Breakthrough pain affects 60-85% of patients and is characterized by onset within seconds to minutes and short duration. We consider breakthrough pain as a sudden, transient, and short-lasting pain that occurs in opioid-treated patients. Breakthrough pain is a temporary worsening of pain in patients with well-controlled underlying pain. Poorly controlled breakthrough pain has a very negative impact on the quality of life of patients. The current treatment options for breakthrough pain include the use of transmucosal fentanyl and, in addition, IR oxycodone. Oxycodone has a relatively rapid onset of action, is well tolerated and easily titrated. It is a welcome enrichment of therapeutic options for treatment of oncological and non-oncological breakthrough pain.
Treatment of tumor pain
06/2018 MUDr. Marek Hakl, Ph.D.
Pain is one of the most common manifestations of oncological illness. Its basic treatment strategy is based on the World Health Organization's three-step ranking. Non-opioid analgetics, weak opioids and strong opioid medication are available for treatment. For the treatment of breakthrough pain, transmucosal fentanyls are now also available. In the treatment of oncological pain, non-invasive administration of analgesics is preferable to invasive, preferring retarded drugs or transdermal opioids, supplemented by fast-release forms for the treatment of acute pain worsening. Analgesic medication can be supplemented with additional comedications, especially from the group of anticonvulsants and antidepressants.
ENTIRE ARTICLE
Pain is one of the most common manifestations of oncological illness. Its basic treatment strategy is based on the World Health Organization's three-step ranking. Non-opioid analgetics, weak opioids and strong opioid medication are available for treatment. For the treatment of breakthrough pain, transmucosal fentanyls are now also available. In the treatment of oncological pain, non-invasive administration of analgesics is preferable to invasive, preferring retarded drugs or transdermal opioids, supplemented by fast-release forms for the treatment of acute pain worsening. Analgesic medication can be supplemented with additional comedications, especially from the group of anticonvulsants and antidepressants.